Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

A large retrospective multicenter study demonstrated the feasibility and efficacy of a short duration of talquetamab bridging therapy before B-cell maturation antigen (BCMA)-targeted chimeric ...

Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.

In the Mithic-FL1 trial, patients with newly diagnosed high-burden follicular lymphoma (FL) demonstrated complete response (CR) rates of 80% and manageable adverse events with outpatient ...

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.

Disease-free and overall survival outcomes were similar across dosing schedules. Patients with high-risk early breast cancer have similar survival outcomes with different dosing schedules of ...

The approval was based on data from a single-arm, phase 3 trial. The US Food and Drug Administration (FDA) has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft ...